Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $30.66, but opened at $35.42. Nanobiotix shares last traded at $30.2460, with a volume of 14,832 shares traded.
Analyst Ratings Changes
NBTX has been the topic of a number of recent analyst reports. Guggenheim began coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, October 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.
View Our Latest Analysis on Nanobiotix
Nanobiotix Stock Performance
The stock has a 50-day simple moving average of $30.34 and a two-hundred day simple moving average of $34.20.
About Nanobiotix
Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.
Further Reading
- Five stocks we like better than Nanobiotix
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
